Literature DB >> 29943155

Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road.

Jing-Si Wang1, Qiu-Yun Zhang2, Jin-Lian Cheng3, Lan-Yu Chen4, Nai-Li Yao5, Gui-Zhi Sun6, Yu-Ling Chu5.   

Abstract

Hepatic fibrosis is a common feature of almost all chronic liver diseases. Formation of new vessels (angiogenesis) is a process strictly related to the progressive fibrogenesis which leads to cirrhosis and liver cancer. This review mainly concerns the relationship between angiogenesis and hepatic fibrosis, by considering the mechanism of angiogenesis, cells in angiogenesis, anti-angiogenic and Chinese medicine therapies.

Entities:  

Keywords:  Chinese medicine; angiogenesis; hepatic fibrosis; review

Mesh：

Substances：

Year:  2018        PMID： 29943155     DOI： 10.1007/s11655-018-3007-1

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN： 1672-0415            Impact factor:   1.978


  103 in total

Review 1.  The fibrinolytic system and matrix metalloproteinases in angiogenesis and tumor progression.

Authors:  Marten A Engelse; Roeland Hanemaaijer; Pieter Koolwijk; Victor W van Hinsbergh
Journal:  Semin Thromb Hemost       Date:  2004-02       Impact factor: 4.180

Review 2.  Review article: angiogenesis soluble factors as liver disease markers.

Authors:  X Salcedo; J Medina; P Sanz-Cameno; L García-Buey; S Martín-Vilchez; R Moreno-Otero
Journal:  Aliment Pharmacol Ther       Date:  2005-07-01       Impact factor: 8.171

3.  Sclerosed hemangioma and sclerosing cavernous hemangioma of the liver: a comparative clinicopathologic and immunohistochemical study with emphasis on the role of mast cells in their histogenesis.

Authors:  Hala R Makhlouf; Kamal G Ishak
Journal:  Liver       Date:  2002-02

4.  Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.

Authors:  Dominique Thabut; Chittaranjan Routray; Gwen Lomberk; Uday Shergill; Kevin Glaser; Robert Huebert; Leena Patel; Tetyana Masyuk; Boris Blechacz; Andrew Vercnocke; Erik Ritman; Richard Ehman; Raul Urrutia; Vijay Shah
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

5.  Identification of a new fibroblast growth factor receptor, FGFR5.

Authors:  M Sleeman; J Fraser; M McDonald; S Yuan; D White; P Grandison; K Kumble; J D Watson; J G Murison
Journal:  Gene       Date:  2001-06-27       Impact factor: 3.688

6.  Effect of Chinese herbal compound on liver fibrosis in rabbits with schistosomiasis by B-ultrasound.

Authors:  Xiao-Lu Liang; Jia-Ying Yuan
Journal:  Asian Pac J Trop Med       Date:  2013-08       Impact factor: 1.226

7.  Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF.

Authors:  Miriam Bueno; Silvia Salgado; Carlos Beas-Zárate; Juan Armendariz-Borunda
Journal:  J Gene Med       Date:  2006-11       Impact factor: 4.565

Review 8.  Evolving therapies for liver fibrosis.

Authors:  Detlef Schuppan; Yong Ook Kim
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

Review 9.  PDGF and vessel maturation.

Authors:  Carina Hellberg; Arne Ostman; C-H Heldin
Journal:  Recent Results Cancer Res       Date:  2010

10.  Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling.

Authors:  Ikuo Nakamura; Kais Zakharia; Bubu A Banini; Dalia S Mikhail; Tae Hyo Kim; Ju Dong Yang; Catherine D Moser; Hassan M Shaleh; Sarah R Thornburgh; Ian Walters; Lewis R Roberts
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.